Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

13 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Genetics of destemming in pepper: A step towards mechanical harvesting.
Hill T, Cassibba V, Joukhadar I, Tonnessen B, Havlik C, Ortega F, Sripolcharoen S, Visser BJ, Stoffel K, Thammapichai P, Garcia-Llanos A, Chen S, Hulse-Kemp A, Walker S, Van Deynze A. Hill T, et al. Among authors: cassibba v. Front Genet. 2023 Mar 17;14:1114832. doi: 10.3389/fgene.2023.1114832. eCollection 2023. Front Genet. 2023. PMID: 37007971 Free PMC article.
Pegaspargase-modified risk-oriented program for adult acute lymphoblastic leukemia: results of the GIMEMA LAL1913 trial.
Bassan R, Chiaretti S, Della Starza I, Spinelli O, Santoro A, Paoloni F, Messina M, Elia L, De Propris MS, Scattolin AM, Audisio E, Marbello L, Borlenghi E, Zappasodi P, Mauro E, Martinelli G, Mattei D, Fracchiolla N, Bocchia M, De Fabritiis P, Bonifacio M, Candoni A, Cassibba V, Di Bartolomeo P, Latte G, Trappolini S, Guarini A, Vitale A, Fazi P, Piciocchi A, Rambaldi A, Foà R. Bassan R, et al. Among authors: cassibba v. Blood Adv. 2023 Aug 22;7(16):4448-4461. doi: 10.1182/bloodadvances.2022009596. Blood Adv. 2023. PMID: 37276451 Free PMC article.
Randomized trial of radiation-free central nervous system prophylaxis comparing intrathecal triple therapy with liposomal cytarabine in acute lymphoblastic leukemia.
Bassan R, Masciulli A, Intermesoli T, Audisio E, Rossi G, Pogliani EM, Cassibba V, Mattei D, Romani C, Cortelezzi A, Corti C, Scattolin AM, Spinelli O, Tosi M, Parolini M, Marmont F, Borlenghi E, Fumagalli M, Cortelazzo S, Gallamini A, Marfisi RM, Oldani E, Rambaldi A. Bassan R, et al. Among authors: cassibba v. Haematologica. 2015 Jun;100(6):786-93. doi: 10.3324/haematol.2014.123273. Epub 2015 Mar 6. Haematologica. 2015. PMID: 25749825 Free PMC article. Clinical Trial.
Different molecular levels of post-induction minimal residual disease may predict hematopoietic stem cell transplantation outcome in adult Philadelphia-negative acute lymphoblastic leukemia.
Bassan R, Spinelli O, Oldani E, Intermesoli T, Tosi M, Peruta B, Borlenghi E, Pogliani EM, Di Bona E, Cassibba V, Scattolin AM, Romani C, Ciceri F, Cortelezzi A, Gianfaldoni G, Mattei D, Audisio E, Rambaldi A. Bassan R, et al. Among authors: cassibba v. Blood Cancer J. 2014 Jul 11;4(7):e225. doi: 10.1038/bcj.2014.48. Blood Cancer J. 2014. PMID: 25014772 Free PMC article. No abstract available.
High cure rates in Burkitt lymphoma and leukemia: a Northern Italy Leukemia Group study of the German short intensive rituximab-chemotherapy program.
Intermesoli T, Rambaldi A, Rossi G, Delaini F, Romani C, Pogliani EM, Pagani C, Angelucci E, Terruzzi E, Levis A, Cassibba V, Mattei D, Gianfaldoni G, Scattolin AM, Di Bona E, Oldani E, Parolini M, Gökbuget N, Bassan R. Intermesoli T, et al. Among authors: cassibba v. Haematologica. 2013 Nov;98(11):1718-25. doi: 10.3324/haematol.2013.086827. Epub 2013 Jun 10. Haematologica. 2013. PMID: 23753030 Free PMC article. Clinical Trial.
Aggressive LGL leukaemia presentation in old age.
Piccin A, Cassibba V, Zambello R, Negri G, Svaldi M, Colombetti V, Cortelazzo S. Piccin A, et al. Among authors: cassibba v. Ann Hematol. 2011 May;90(5):603-6. doi: 10.1007/s00277-010-1059-1. Epub 2010 Sep 4. Ann Hematol. 2011. PMID: 20821011 No abstract available.
Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL).
Bassan R, Spinelli O, Oldani E, Intermesoli T, Tosi M, Peruta B, Rossi G, Borlenghi E, Pogliani EM, Terruzzi E, Fabris P, Cassibba V, Lambertenghi-Deliliers G, Cortelezzi A, Bosi A, Gianfaldoni G, Ciceri F, Bernardi M, Gallamini A, Mattei D, Di Bona E, Romani C, Scattolin AM, Barbui T, Rambaldi A. Bassan R, et al. Among authors: cassibba v. Blood. 2009 Apr 30;113(18):4153-62. doi: 10.1182/blood-2008-11-185132. Epub 2009 Jan 13. Blood. 2009. PMID: 19141862 Free article.
Gemtuzumab ozogamicin (Mylotarg) as single-agent treatment for frail patients 61 years of age and older with acute myeloid leukemia: final results of AML-15B, a phase 2 study of the European Organisation for Research and Treatment of Cancer and Gruppo Italiano Malattie Ematologiche dell'Adulto Leukemia Groups.
Amadori S, Suciu S, Stasi R, Willemze R, Mandelli F, Selleslag D, Denzlinger C, Muus P, Stauder R, Berneman Z, Pruijt J, Nobile F, Cassibba V, Marie JP, Beeldens F, Baila L, Vignetti M, de Witte T. Amadori S, et al. Among authors: cassibba v. Leukemia. 2005 Oct;19(10):1768-73. doi: 10.1038/sj.leu.2403901. Leukemia. 2005. PMID: 16079891 Clinical Trial.
13 results